Kamyar Kalantar-Zadeh M.D. to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
1.251
-
Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. JAMA Netw Open. 2018 10 05; 1(6):e182311.
Score: 0.602
-
Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans). Am J Cardiol. 2022 05 01; 170:47-55.
Score: 0.191
-
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019 11; 290:59-65.
Score: 0.161
-
Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes. J Am Heart Assoc. 2019 03 19; 8(6):e011869.
Score: 0.155
-
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy. Int Urol Nephrol. 2014 Jan; 46(1):27-39.
Score: 0.102
-
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 11; 217:72-83.
Score: 0.040